digital health companies weight loss glp-1 Miami's eMed just hit a $2 billion valuation—and Tom Brady is now its chief wellness officer. The company raised $200 million in series A funding to advance its AI-powered platform GLP-1 Weight Loss Medication |

Tirzepatide, a dual GIP/GLP-1 receptor agonist, has shown even greater efficacy in some studies, with weight reductions of approximately 20% in the SURMOUNT-1 trial

Additional blood tests are conducted to assess liver function and check for signs of liver inflammation or scarring

10.1016/j.ccr.2006.08.015 Cancer Cell 164 SenaL

Research Methodology The researchers used structured secondary data analysis to analyze peer-reviewed studies, experimental datasets, and clinical reports

These figures are averages and individual results may vary depending on diet, physical activity, insulin resistance, and overall health

Heres a breakdown of what BPC-157 actually is, how its believed to work in experimental models, and where the current research stands